Recital 14, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 4×

Provision should be made for the quality, safety and efficacy criteria in Directives 2001/83/EC and 2001/82/EC to apply to medicinal products authorised by the Community and it should be possible to assess the risk-benefit balance of all medicinal products when they are placed on the market, at the time of the renewal of the authorisation and at any other time the competent authority deems appropriate.

  • Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision

    24 Apr 2009 · 62009TO0052

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    In that regard, it must be stated that a medicinal product’s SmPC cannot but be interpreted strictly. Before granting an MA, including in the context of the variation or extension of an existing MA, the competent authority must ensure, …

    23 Sep 2020 · 62019TJ0549

  • Opinion of Advocate General Sharpston delivered on 22 April 2010. European Commission v Republic of Lithuania.Decision

    That can be derived from the fact that, in Regulation No 726/2004, recital 14 provides that the quality, safety and efficacy criteria laid down in Directives 2001/82 and 2001/83 are to apply to medicinal products authorised by the …

    22 Apr 2010 · 62008CC0350

  • Opinion of Advocate General Medina delivered on 6 October 2022. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    I observe further that, irrespective of the procedure followed for the authorisation of a medicinal product – national or centralised – the harmonised nature of EU pharmaceutical legislation is reflected in recital 14 of Regulation No …

    6 Oct 2022 · 62021CC0438